Paper · 36976456
Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.
Sangro P and 3 others. J Physiol Biochem, 2023. Cited by 119 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. Papers, record 36976456. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36976456
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Non-alcoholic Fatty Liver Disease | Major topic |
| Humans | |
| Disease Progression | |
| Inflammation | |
| Liver Cirrhosis |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References65
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21,848,324 | When galectins recognize glycans: from biochemistry to physiology and back again. | Biochemistry | 2011 | https://conductscience.org/library/papers/21848324 | PubMed |
| 2 | 24,222,941 | PNPLA3 I148M polymorphism and progressive liver disease. | World J Gastroenterol | 2013 | https://conductscience.org/library/papers/24222941 | PubMed |
| 3 | 30,067,154 | Mechanisms of Insulin Action and Insulin Resistance. | Physiol Rev | 2018 | https://conductscience.org/library/papers/30067154 | PubMed |
| 4 | 21,295,846 | National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. | Lancet | 2011 | https://conductscience.org/library/papers/21295846 | PubMed |
| 5 | 20,176,643 | Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. | Gut | 2010 | https://conductscience.org/library/papers/20176643 | PubMed |
| 6 | 15,146,238 | Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. | J Clin Invest | 2004 | https://conductscience.org/library/papers/15146238 | PubMed |
| 7 | 19,359,429 | Inflammasome-mediated regulation of hepatic stellate cells. | Am J Physiol Gastrointest Liver Physiol | 2009 | https://conductscience.org/library/papers/19359429 | PubMed |
| 8 | 31,731,005 | A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. | Contemp Clin Trials | 2020 | https://conductscience.org/library/papers/31731005 | PubMed |
| 9 | 16,890,538 | Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. | Cell Metab | 2006 | https://conductscience.org/library/papers/16890538 | PubMed |
| 10 | 29,159,325 | Role of Aramchol in steatohepatitis and fibrosis in mice. | Hepatol Commun | 2017 | https://conductscience.org/library/papers/29159325 | PubMed |
1 to 10 of 65
See all 65 referencesCited by78
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 119 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,579,267 | Short-Term Impact of Endoscopic Gastric Remodeling in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis. | Obes Surg | 2026 | https://conductscience.org/library/papers/42579267 | PubMed |
| 42,534,806 | Plant metabolites targeting the AMPK pathway: advances in the mechanisms of action in the context of MAFLD. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42534806 | PubMed |
| 42,487,340 | Burden of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive US Healthcare Analysis. | J Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42487340 | PubMed |
| 42,446,679 | Unrevealing the Role of Flavonoids in Mitigation of Non-Alcoholic Fatty Liver Disease. | Med Chem Res | 2026 | https://conductscience.org/library/papers/42446679 | PubMed |
| 42,212,530 | Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine-to-Caffeine Metabolic Ratio: A Pharmacokinetic Study. | J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42212530 | PubMed |
| 42,121,292 | Glucagon-like peptide-1 receptor agonists improve hepatic histology and metabolic parameters in type 2 diabetes with MASLD: a meta-analysis of randomized controlled trials. | Diabetol Metab Syndr | 2026 | https://conductscience.org/library/papers/42121292 | PubMed |
| 42,075,864 | Effects of Chaenomeles japonica Fruit Juice on Energy Balance and Biochemical and Histological Parameters in a Model of Diet-Induced Metabolic Syndrome in Rats. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42075864 | PubMed |
| 42,064,079 | Integrated bioinformatics and machine learning identify early diagnostic biomarkers for MAFLD with comorbid psoriasis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42064079 | PubMed |
| 42,007,332 | Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/42007332 | PubMed |
| 41,993,620 | Context-dependent Activities of Mitrephorone Link Lipid Redirection, Anti-inflammatory Action, and Ferroptosis Control to Hepatocyte Protection. | Theranostics | 2026 | https://conductscience.org/library/papers/41993620 | PubMed |
1 to 10 of 78
See all 78 cited byGenes39
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ANGPTL4 | 51,129 | PubTator's text mining | https://conductscience.org/library/genes/51129 | NCBI Gene |
| APOC3 | 345 | PubTator's text mining | https://conductscience.org/library/genes/345 | NCBI Gene |
| CNR1 | 1,268 | PubTator's text mining | https://conductscience.org/library/genes/1268 | NCBI Gene |
| CYP7A1 | 1,581 | PubTator's text mining | https://conductscience.org/library/genes/1581 | NCBI Gene |
| ENPP1 | 5,167 | PubTator's text mining | https://conductscience.org/library/genes/5167 | NCBI Gene |
| FGF19 | 9,965 | PubTator's text mining | https://conductscience.org/library/genes/9965 | NCBI Gene |
| FGF21 | 26,291 | PubTator's text mining | https://conductscience.org/library/genes/26291 | NCBI Gene |
| GCK | 2,645 | PubTator's text mining | https://conductscience.org/library/genes/2645 | NCBI Gene |
| GCKR | 2,646 | PubTator's text mining | https://conductscience.org/library/genes/2646 | NCBI Gene |
| GGT1 | 2,678 | PubTator's text mining | https://conductscience.org/library/genes/2678 | NCBI Gene |
1 to 10 of 39
See all 39 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36976456
GET https://conductscience.org/api/papers/v1/36976456/references?page=2